Literature DB >> 7638762

Blockade of endothelin-converting enzyme reduces pulmonary hypertension after cardiopulmonary bypass and circulatory arrest.

P M Kirshbom1, S S Tsui, L R DiBernardo, J N Meliones, D A Schwinn, R M Ungerleider, J W Gaynor.   

Abstract

BACKGROUND: Pulmonary dysfunction associated with elevated pulmonary vascular resistance is a significant problem after cardiopulmonary bypass (CPB) and circulatory arrest. Mediators of the pulmonary hypertensive response to CPB have not been fully elucidated. The purpose of this study was to examine the contribution of the endothelium-derived vasoconstrictor endothelin-1 to postbypass pulmonary hypertension.
METHODS: Twelve 1-month-old piglets were instrumented with left atrial and pulmonary artery (PA) micromanometers and a PA flow probe. Phosphoramidon (Phos, n = 6) pigs received a 30 mg/kg bolus of Phos, an endothelin converting enzyme inhibitor. Controls (n = 6) received saline solution. All animals were placed on CPB and underwent a 60-minute period of circulatory arrest. The indexed pulmonary vascular resistance (PVRI) was calculated at baseline for controls, both before and 10 minutes after drug infusion in the Phos group, and 15 minutes after separation from CPB in both groups.
RESULTS: Pre-CPB, mean PA pressure, and PVRI were not different between the control and Phos groups (14.6 +/- 1.1 versus 14.5 +/- 1.1 mm Hg and 7322 +/- 1269 versus 7260 +/- 947 dyne/sec/kg/cm-5, respectively). After CPB mean PA pressure was significantly higher in control than Phos animals (32.1 +/- 1.1 versus 22.5 +/- 1.3 mm Hg, p = 0.0003). PVRI was also significantly higher in the controls (30896 +/- 4714 versus 14972 +/- 1710, dyne/sec/kg/cm-5, p = 0.02).
CONCLUSIONS: Production of endothelin-1 during CPB and circulatory arrest is a mediator of postbypass pulmonary hypertension.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7638762     DOI: 10.1016/s0039-6060(05)80356-3

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  2 in total

1.  Early therapeutic experience with the endothelin antagonist BQ-123 in pulmonary hypertension after congenital heart surgery.

Authors:  B Prendergast; D E Newby; L E Wilson; D J Webb; P S Mankad
Journal:  Heart       Date:  1999-10       Impact factor: 5.994

2.  Acute endothelin A receptor antagonism improves pulmonary and systemic haemodynamics in patients with pulmonary arterial hypertension that is primary or autoimmune and related to congenital heart disease.

Authors:  S C Apostolopoulou; S Rammos; Z S Kyriakides; D J Webb; N R Johnston; D V Cokkinos; D Th Kremastinos
Journal:  Heart       Date:  2003-10       Impact factor: 5.994

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.